Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBT Margin (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed EBT Margin for 5 consecutive years, with 15203.74% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBT Margin rose 1799143.0% year-over-year to 15203.74%, compared with a TTM value of 194727.52% through Jun 2025, up 19617785.0%, and an annual FY2024 reading of 3171.7%, down 128720.0% over the prior year.
  • EBT Margin was 15203.74% for Q2 2025 at SAB Biotherapeutics, up from 8669.15% in the prior quarter.
  • Across five years, EBT Margin topped out at 15203.74% in Q2 2025 and bottomed at 8669.15% in Q4 2024.
  • Average EBT Margin over 5 years is 922.56%, with a median of 280.18% recorded in 2022.
  • The sharpest move saw EBT Margin tumbled -796947bps in 2023, then soared 1799143bps in 2025.
  • Year by year, EBT Margin stood at 104.46% in 2021, then crashed by -248bps to 363.23% in 2022, then plummeted by -1963bps to 7493.75% in 2023, then dropped by -16bps to 8669.15% in 2024, then surged by 275bps to 15203.74% in 2025.
  • Business Quant data shows EBT Margin for SABS at 15203.74% in Q2 2025, 8669.15% in Q4 2024, and 2787.69% in Q2 2024.